Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Prospective observational study of emicizumab in infants with congenital hemophilia A
jRCT1031230264Active, not recruiting
- Sponsor
- Chugai Pharmaceutical Co., Ltd.
- Start
- Aug 2023
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Open-label, single-arm trial of emicizumab in hemophilia A, sponsored by Chugai Pharmaceutical Co., Ltd. Primary endpoint: Primary: Relationship between coagulation test parameters and plasma emicizumab levels (6–12 months). Started Aug 2023; status: active, not recruiting.
02
Drugs
emicizumab
03
Conditions
hemophilia A
Beyond the preview
Go deeper on jRCT1031230264.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT1031230264.